A buyer scorecard for separating completed tests, biomarker changes, functional progress, patient-important outcomes, safety, and unresolved follow-up.
A 2026 buyer guide to AI diagnostics in longevity clinics: real use cases, red flags, physician oversight, FDA caveats, and questions before you pay.
A buyer guide to longevity blood panels: decision-relevant tests, selective add-ons, exploratory biomarkers, repeat-testing logic, and commercial red flags.
A patient-safety guide to longevity clinic governance: medical accountability, evidence labels, diagnostics, AI, biomarkers, records, adverse events, and conflicts.
This weekly WLC intelligence digest covers serious clinic standards, AI diagnostics, GLP-1 programs, full-body MRI, biological-age testing, and peptides.
A dated May 2026 evidence check on five longevity-clinic trends: AI diagnostics, GLP-1s, biomarkers, imaging, and changing care models.
This week's radar covers blood-based Alzheimer's biomarkers, FDA-cleared imaging AI, DXA/DEXA upgrades, wearable VO₂ estimates, and smarter questions for buyers.
A practical buyer’s guide to longevity health assessments: biomarkers, imaging, genetics, fitness testing, costs, and the questions to ask before booking.
ARPA-H's PROSPR program funds seven teams with up to $144 million. Here is what the program is testing, what its milestones mean, and why it is not yet validation of a healthspan treatment.
